Annovis Bio
ANVS
28 hedge funds and large institutions have $18.3M invested in Annovis Bio in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
58% more capital invested
Capital invested by funds: $11.6M → $18.3M (+$6.7M)
22% more funds holding
Funds holding: 23 → 28 (+5)
4.97% more ownership
Funds ownership: 9.22% → 14.19% (+5%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.93M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$1.48M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$144K |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$143K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$229K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$213K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$28.9K |
| 4 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$7.07K |
| 5 |
Morgan Stanley
New York
|
-$4.09K |
ANVS Hedge Fund Activity: Q2 2023 in Review
28 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q2 2023, worth a combined $18.3M — up 58% from $11.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ANVS positions and 3 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $5.93M. The largest seller was Jane Street, exiting entirely with an estimated $229K sold.
- 28 institutional investors held Annovis Bio (ANVS) as of Q2 2023, up from 23 in Q1 2023.
- Funds reported $18.3M of Annovis Bio stock for Q2 2023, up 58% quarter-over-quarter.
- 8 funds opened new Annovis Bio positions in Q2 2023 and 3 closed out, a net change of +5 holders.
- The largest Annovis Bio buyer in Q2 2023 was AIGH Capital Management, an estimated $5.93M added.
- The largest Annovis Bio seller in Q2 2023 was Jane Street, an estimated $229K sold.
Based on aggregated 13F filings for Q2 2023.